{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T07:18:03Z","timestamp":1791443883893,"version":"4.3.3"},"reference-count":67,"publisher":"American Association for the Advancement of Science (AAAS)","issue":"635","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Sci. Transl. Med."],"published-print":{"date-parts":[[2022,3,9]]},"abstract":"<jats:p>Despite the success of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines, there remains a need for more prevention and treatment options for individuals remaining at risk of coronavirus disease 2019 (COVID-19). Monoclonal antibodies (mAbs) against the viral spike protein have potential to both prevent and treat COVID-19 and reduce the risk of severe disease and death. Here, we describe AZD7442, a combination of two mAbs, AZD8895 (tixagevimab) and AZD1061 (cilgavimab), that simultaneously bind to distinct, nonoverlapping epitopes on the spike protein receptor binding domain to neutralize SARS-CoV-2. Initially isolated from individuals with prior SARS-CoV-2 infection, the two mAbs were designed to extend their half-lives and reduce effector functions. The AZD7442 mAbs individually prevent the spike protein from binding to angiotensin-converting enzyme 2 receptor, blocking virus cell entry, and neutralize all tested SARS-CoV-2 variants of concern. In a nonhuman primate model of SARS-CoV-2 infection, prophylactic AZD7442 administration prevented infection, whereas therapeutic administration accelerated virus clearance from the lung. In an ongoing phase 1 study in healthy participants (NCT04507256), a 300-mg intramuscular injection of AZD7442 provided SARS-CoV-2 serum geometric mean neutralizing titers greater than 10-fold above those of convalescent serum for at least 3 months, which remained threefold above those of convalescent serum at 9 months after AZD7442 administration. About 1 to 2% of serum AZD7442 was detected in nasal mucosa, a site of SARS-CoV-2 infection. Extrapolation of the time course of serum AZD7442 concentration suggests AZD7442 may provide up to 12 months of protection and benefit individuals at high-risk of COVID-19.<\/jats:p>","DOI":"10.1126\/scitranslmed.abl8124","type":"journal-article","created":{"date-parts":[[2022,1,25]],"date-time":"2022-01-25T10:26:58Z","timestamp":1643106418000},"source":"Crossref","is-referenced-by-count":206,"title":["The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in nonhuman primates and has an extended half-life in humans"],"prefix":"10.1126","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6294-7273","authenticated-orcid":true,"given":"Yueh-Ming","family":"Loo","sequence":"first","affiliation":[{"name":"Virology and Vaccine Discovery, Vaccines and Immune Therapies, BioPharmaceuticals R&amp;D, AstraZeneca, Gaithersburg, MD 20878, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4305-3068","authenticated-orcid":true,"given":"Patrick M.","family":"McTamney","sequence":"additional","affiliation":[{"name":"Virology and Vaccine Discovery, Vaccines and Immune Therapies, BioPharmaceuticals R&amp;D, AstraZeneca, Gaithersburg, MD 20878, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3878-8601","authenticated-orcid":true,"given":"Rosalinda H.","family":"Arends","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&amp;D, AstraZeneca, Gaithersburg, MD 20878, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6505-7281","authenticated-orcid":true,"given":"Michael E.","family":"Abram","sequence":"additional","affiliation":[{"name":"Translational Medicine, Vaccines and Immune Therapies, BioPharmaceuticals R&amp;D, AstraZeneca, Gaithersburg, MD 20878, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasia A.","family":"Aksyuk","sequence":"additional","affiliation":[{"name":"Translational Medicine, Vaccines and Immune Therapies, BioPharmaceuticals R&amp;D, AstraZeneca, Gaithersburg, MD 20878, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7739-4349","authenticated-orcid":true,"given":"Seme","family":"Diallo","sequence":"additional","affiliation":[{"name":"Virology and Vaccine Discovery, Vaccines and Immune Therapies, BioPharmaceuticals R&amp;D, AstraZeneca, Gaithersburg, MD 20878, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"Flores","sequence":"additional","affiliation":[{"name":"Virology and Vaccine Discovery, Vaccines and Immune Therapies, BioPharmaceuticals R&amp;D, AstraZeneca, Gaithersburg, MD 20878, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6988-8576","authenticated-orcid":true,"given":"Elizabeth J.","family":"Kelly","sequence":"additional","affiliation":[{"name":"Translational Medicine, Vaccines and Immune Therapies, BioPharmaceuticals R&amp;D, AstraZeneca, Gaithersburg, MD 20878, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuishu","family":"Ren","sequence":"additional","affiliation":[{"name":"Virology and Vaccine Discovery, Vaccines and Immune Therapies, BioPharmaceuticals R&amp;D, AstraZeneca, Gaithersburg, MD 20878, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0964-8455","authenticated-orcid":true,"given":"Richard","family":"Roque","sequence":"additional","affiliation":[{"name":"Virology and Vaccine Discovery, Vaccines and Immune Therapies, BioPharmaceuticals R&amp;D, AstraZeneca, Gaithersburg, MD 20878, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Rosenthal","sequence":"additional","affiliation":[{"name":"Virology and Vaccine Discovery, Vaccines and Immune Therapies, BioPharmaceuticals R&amp;D, AstraZeneca, Gaithersburg, MD 20878, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie","family":"Streicher","sequence":"additional","affiliation":[{"name":"Translational Medicine, Vaccines and Immune Therapies, BioPharmaceuticals R&amp;D, AstraZeneca, Gaithersburg, MD 20878, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin M.","family":"Tuffy","sequence":"additional","affiliation":[{"name":"Translational Medicine, Vaccines and Immune Therapies, BioPharmaceuticals R&amp;D, AstraZeneca, Gaithersburg, MD 20878, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0312-7360","authenticated-orcid":true,"given":"Nicholas J.","family":"Bond","sequence":"additional","affiliation":[{"name":"Analytical Sciences, BioPharmaceuticals R&amp;D, AstraZeneca, Granta Park, Cambridge CB21 6GH, UK."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Owen","family":"Cornwell","sequence":"additional","affiliation":[{"name":"Analytical Sciences, BioPharmaceuticals R&amp;D, AstraZeneca, Granta Park, Cambridge CB21 6GH, UK."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8077-6025","authenticated-orcid":true,"given":"Jerome","family":"Bouquet","sequence":"additional","affiliation":[{"name":"Integrated Bioanalysis, Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&amp;D, AstraZeneca, San Francisco, CA 94080, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3056-1891","authenticated-orcid":true,"given":"Lily I.","family":"Cheng","sequence":"additional","affiliation":[{"name":"Oncology Safety Pathology, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&amp;D, AstraZeneca, Gaithersburg, MD 20878, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2484-7359","authenticated-orcid":true,"given":"James","family":"Dunyak","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology and Pharmacometrics, BioPharmaceuticals R&amp;D, AstraZeneca, Gaithersburg, MD 20878, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2788-0856","authenticated-orcid":true,"given":"Yue","family":"Huang","sequence":"additional","affiliation":[{"name":"Integrated Bioanalysis, Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&amp;D, AstraZeneca, San Francisco, CA 94080, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1939-951X","authenticated-orcid":true,"given":"Anton I.","family":"Rosenbaum","sequence":"additional","affiliation":[{"name":"Integrated Bioanalysis, Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&amp;D, AstraZeneca, San Francisco, CA 94080, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7786-4371","authenticated-orcid":true,"given":"Venkatesh","family":"Pilla Reddy","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology and Pharmacometrics, BioPharmaceuticals R&amp;D, AstraZeneca, Granta Park, Cambridge CB21 6GH, UK."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1103-9608","authenticated-orcid":true,"given":"Hanne","family":"Andersen","sequence":"additional","affiliation":[{"name":"BIOQUAL Inc., Rockville, MD 20850, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5230-1532","authenticated-orcid":true,"given":"Robert H.","family":"Carnahan","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN 37232, USA."},{"name":"Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN 37232, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0049-1079","authenticated-orcid":true,"suffix":"Jr.","given":"James E.","family":"Crowe","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN 37232, USA."},{"name":"Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN 37232, USA."},{"name":"Department of Pathology, Microbiology and Immunology, Vanderbilt University, Nashville, TN 37232, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana I.","family":"Kuehne","sequence":"additional","affiliation":[{"name":"USAMRIID, Fort Detrick, MD 21702-5011, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew S.","family":"Herbert","sequence":"additional","affiliation":[{"name":"USAMRIID, Fort Detrick, MD 21702-5011, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0883-5016","authenticated-orcid":true,"given":"John M.","family":"Dye","sequence":"additional","affiliation":[{"name":"USAMRIID, Fort Detrick, MD 21702-5011, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4663-7800","authenticated-orcid":true,"given":"Helen","family":"Bright","sequence":"additional","affiliation":[{"name":"Virology and Vaccine Discovery, Vaccines and Immune Therapies, BioPharmaceuticals R&amp;D, AstraZeneca, Gaithersburg, MD 20878, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole L.","family":"Kallewaard","sequence":"additional","affiliation":[{"name":"Virology and Vaccine Discovery, Vaccines and Immune Therapies, BioPharmaceuticals R&amp;D, AstraZeneca, Gaithersburg, MD 20878, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9783-0956","authenticated-orcid":true,"given":"Menelas N.","family":"Pangalos","sequence":"additional","affiliation":[{"name":"BioPharmaceuticals R&amp;D, AstraZeneca, Cambridge CB21 6GH, UK."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1689-3475","authenticated-orcid":true,"given":"Mark T.","family":"Esser","sequence":"additional","affiliation":[{"name":"Vaccines and Immune Therapies, BioPharmaceuticals R&amp;D, AstraZeneca, Gaithersburg, MD 20878, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"221","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n1088"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00947-8"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.03500321"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2021.05.029"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00213-8"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.4385"},{"key":"e_1_3_3_8_2","doi-asserted-by":"crossref","unstructured":"M. Agha M. Blake C. Chilleo A. Wells G. Haidar Suboptimal response to COVID-19 mRNA vaccines in hematologic malignancies patients. medRxiv 2021.04.06.21254949 [Preprint]. 7 April 2021. https:\/\/doi.org\/10.1101\/2021.04.06.21254949.","DOI":"10.1101\/2021.04.06.21254949"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2109072"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.10245"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2020.03.007"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.abd7728"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2020.112937"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01377-8"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.0202"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107934"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2035002"},{"key":"e_1_3_3_18_2","unstructured":"ClinicalTrials.gov \u201cPhase III double-blind placebo-controlled study of AZD7442 for post- exposure prophylaxis of COVID-19 in adults (STORM CHASER)\u201d (2020); https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04625972."},{"key":"e_1_3_3_19_2","unstructured":"ClinicalTrials.gov \u201cPhase III double-blind placebo-controlled study of AZD7442 for pre-exposure prophylaxis of COVID-19 in adult (PROVENT)\u201d (2020); https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04625725."},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2548-6"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01285-13"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01020-16"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1107\/S0907444908007877"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/jps.20178"},{"key":"e_1_3_3_25_2","doi-asserted-by":"crossref","unstructured":"J. Dong S. J. Zost A. J. Greaney T. N. Starr A. S. Dingens E. C. Chen R. E. Chen J. B. Case R. E. Sutton P. Gilchuk J. Rodriguez E. Armstrong C. Gainza R. S. Nargi E. Binshtein X. Xie X. Zhang P.-Y. Shi J. Logue S. Weston M. E. McGrath M. B. Frieman T. Brady K. Tuffy H. Bright Y.-M. Loo P. McTamney M. Esser R. H. Carnahan M. S. Diamond J. D. Bloom J. E. Crowe Genetic and structural basis for recognition of SARS-CoV-2 spike protein by a two-antibody cocktail. bioRxiv 2021.2001.2027.428529 [Preprint]. 1 March 2021. https:\/\/doi.org\/10.1101\/2021.01.27.428529.","DOI":"10.1101\/2021.01.27.428529"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0998-x"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.06.043"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.abe8499"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03720-y"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01294-w"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2021.03.055"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2021.02.037"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.abd0831"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03398-2"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2021.04.007"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2021.06.020"},{"key":"e_1_3_3_37_2","doi-asserted-by":"crossref","unstructured":"L. A. VanBlargan J. M. Errico P. J. Halfmann S. J. Zost J. E. Crowe L. A. Purcell Y. Kawaoka D. Corti D. H. Fremont M. S. Diamond An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by several therapeutic monoclonal antibodies. bioRxiv 12.15.472828 [Preprint]. 17 December 2021. https:\/\/doi.org\/10.1101\/2021.12.15.472828.","DOI":"10.21203\/rs.3.rs-1175516\/v1"},{"key":"e_1_3_3_38_2","doi-asserted-by":"crossref","unstructured":"W. Dejnirattisai J. Huo D. Zhou J. Zahradn\u00edk P. Supasa C. Liu H. M. E. Duyvesteyn H. M. Ginn A. J. Mentzer A. Tuekprakhon R. Nutalai B. Wang A. Dijokaite S. Khan O. Avinoam M. Bahar D. Skelly S. Adele S. A. Johnson A. Amini T. Ritter C. Mason C. Dold D. Pan S. Assadi A. Bellass N. Omo-Dare D. Koeckerling A. Flaxman D. Jenkin P. K. Aley M. Voysey S. A. Costa Clemens F. G. Naveca V. Nascimento F. Nascimento C. Fernandes da Costa P. C. Resende A. Pauvolid-Correa M. M. Siqueira V. Baillie N. Serafin Z. Ditse K. D. Silva S. Madhi M. C. Nunes T. Malik P. J. Openshaw J. K. Baillie M. G. Semple A. R. Townsend K.-Y. A. Huang T. K. Tan M. W. Carroll P. Klenerman E. Barnes S. J. Dunachie B. Constantinides H. Webster D. Crook A. J. Pollard T. Lambe; OPTIC consortium; ISARIC4C consortium N. G. Paterson M. A. Williams D. R. Hall E. E. Fry J. Mongkolsapaya J. Ren G. Schreiber D. I. Stuart G. R. Screaton Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses. bioRxiv 12.03.471045 [Preprint]. 22 December 2021. https:\/\/doi.org\/10.1101\/2021.12.03.471045.","DOI":"10.1101\/2021.12.03.471045"},{"key":"e_1_3_3_39_2","doi-asserted-by":"crossref","unstructured":"T. Zhou L. Wang J. Misasi A. Pegu Y. Zhang D. R. Harris A. S. Olia C. A. Talana E. S. Yang M. Chen M. Choe W. Shi I.-T. Teng A. Creanga C. Jenkins K. Leung T. Liu E.-S. D. Stancofski T. Stephens B. Zhang Y. Tsybovsky B. S. Graham J. R. Mascola N. J. Sullivan P. D. Kwong Structural basis for potent antibody neutralization of SARS-CoV-2 variants including B.1.1.529. bioRxiv 2021.2012.2027.474307 [Preprint]. 28 December 2021. https:\/\/doi.org\/10.1101\/2021.12.27.474307.","DOI":"10.1126\/science.abn8897"},{"key":"e_1_3_3_40_2","unstructured":"FNIH \u201cOpenData Portal. SARS-CoV-2 variants and therapeutics. Therapeutic activity explorer\u201d (2022); https:\/\/opendata.ncats.nih.gov\/variant\/datasets?id=160."},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41564-020-00789-5"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2021.02.026"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20201993"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-04017-w"},{"key":"e_1_3_3_45_2","doi-asserted-by":"crossref","unstructured":"RECOVERY Collaborative Group P. W. Horby M. Mafham L. Peto M. Campbell G. Pessoa-Amorim E. Spata N. Staplin J. R. Emberson B. Prudon P. Hine T. Brown C. A. Green R. Sarkar P. Desai B. Yates T. Bewick S. Tiberi T. Felton J. K. Baillie M. H. Buch L. C. Chappell J. N. Day S. N. Faust T. Jaki K. Jeffery E. Juszczak W. S. Lim A. Montgomery A. Mumford K. Rowan G. Thwaites D. M. Weinreich R. Haynes M. J. Landray Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): A randomised controlled open-label platform trial. medRxiv 2021.2006.2015.21258542 [Preprint]. 16 June 2021. https:\/\/doi.org\/10.1101\/2021.06.15.21258542.","DOI":"10.1101\/2021.06.15.21258542"},{"key":"e_1_3_3_46_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2109682"},{"key":"e_1_3_3_47_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.8828"},{"key":"e_1_3_3_48_2","doi-asserted-by":"crossref","unstructured":"M. Levin A. Ustianowski S. De Wit O. Launay M. Avila S. Seegobin A. Templeton Y. Yuan P. Ambery H. R. Arends R. Beavon K. A. Near K. W. Padilla K. Psachoulia A. Sharbaugh K. Streicher M. N. Pangalos M. T. Esser R. A. Gasser PROVENT: Phase 3 study of efficacy and safety of AZD7442 (tixagevimab\/cilgavimab) for pre-exposure prophylaxis of COVID-19 in adults. IDWeek 2021 Virtual. Abstract LB5.","DOI":"10.1093\/ofid\/ofab466.1646"},{"key":"e_1_3_3_49_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1913556"},{"key":"e_1_3_3_50_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M604292200"},{"key":"e_1_3_3_51_2","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaj1928"},{"key":"e_1_3_3_52_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.abe2402"},{"key":"e_1_3_3_53_2","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abf1906"},{"key":"e_1_3_3_54_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2423-5"},{"key":"e_1_3_3_55_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m3862"},{"key":"e_1_3_3_56_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.abc4776"},{"key":"e_1_3_3_57_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2607-z"},{"key":"e_1_3_3_58_2","doi-asserted-by":"publisher","DOI":"10.1186\/1743-422X-2-84"},{"key":"e_1_3_3_59_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.abb2507"},{"key":"e_1_3_3_60_2","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000001916"},{"key":"e_1_3_3_61_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01714-16"},{"key":"e_1_3_3_62_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30995-6"},{"key":"e_1_3_3_63_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1809697"},{"key":"e_1_3_3_64_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(19)30076-1"},{"key":"e_1_3_3_65_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1912196"},{"key":"e_1_3_3_66_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-34171-7"},{"key":"e_1_3_3_67_2","doi-asserted-by":"publisher","DOI":"10.1007\/s13361-018-2067-y"},{"key":"e_1_3_3_68_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2020.06.010"}],"container-title":["Science Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.science.org\/doi\/pdf\/10.1126\/scitranslmed.abl8124","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,16]],"date-time":"2024-01-16T13:39:53Z","timestamp":1705412393000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.science.org\/doi\/10.1126\/scitranslmed.abl8124"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,9]]},"references-count":67,"journal-issue":{"issue":"635","published-print":{"date-parts":[[2022,3,9]]}},"alternative-id":["10.1126\/scitranslmed.abl8124"],"URL":"https:\/\/doi.org\/10.1126\/scitranslmed.abl8124","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.08.30.21262666","asserted-by":"object"}]},"ISSN":["1946-6234","1946-6242"],"issn-type":[{"value":"1946-6234","type":"print"},{"value":"1946-6242","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,9]]},"article-number":"eabl8124"}}